Abstract Number: PB0269
Meeting: ISTH 2021 Congress
Background: Since the pandemic caused by severe acute respiratory syndrome coronavirus-2(SARS-CoV2), known as COVID-19, has started in February 2020, different cases of immune thrombocytopenia (ITP) in patients (pts) affected by SARS-CoV2 have been reported. The management of COVID-19 in pts with simultaneous/previous ITP is challenging for the involvement of the haemostatic system.
Aims: To describe the management and outcome of pts with ITP and COVID-19.
Methods: Data were collected from clinical charts. All pts expressed their agreement.
Results: 17 pts had RT-PCR confirmed SARS-CoV2 infection on a nasopharyngeal swab (October 2020-January 2021). Six pts were male (35.3%), 11 female (64.7%); median age 57 years (30-90). At the time of the infection, as regards ITP, pts were grouped as follows: 3 had simultaneous newly-diagnosed (ND) ITP (17.6%) and 1 experienced a relapse (5.8%) [median platelet count 5.5×109/L (2-30×109/L)]; 7 had chronic ITP on treatment (41.2%) (eltrombopag, n=5; romiplostim, n=1; prednisone, n=1) and 2 had stable chronic ITP off-therapy (11.8%) [(median platelet count 63×109/L (30-100×109/L)]; 4 pts had a previous ITP (complete responders, CR) on follow-up (23.6%) (platelet count >100×109/L). Only 2 pts had no COVID-related symptoms (11.8%). The most common symptoms were fever, anosmia, articular pain, mild-to-moderate respiratory distress. Three pts required hospitalization for acute platelet decrease and mucocutaneous bleeding (ND-ITP, n=2; relapse, n=1) and were responsive to intravenous dexamethasone (40 mg/day, days 1-4) and immunoglobulins (1 g/kg) (17.6%). Three pts were hospitalized for pneumonia (ND-ITP, n=1; chronic ITP, n=1; CR, n=1) and required antibiotics and oral corticosteroid (17.6%). Eleven pts recovered at home without bleeding; their platelet count did not show any change at the evaluation after quarantine (64.7%). All pts had seroconversion; no death occurred.
Conclusions: ND-ITP triggered by COVID-19 is responsive to immunoglobulins and steroids. Outcome is favourable also for COVID-19 pts with off-therapy or on treatment ITP.
To cite this abstract in AMA style:Lapietra G, Ferretti A, Baldacci E, De Luca ML, Aprile SM, Barone F, Olivieri S, Chistolini A, Santoro C. Immune Thrombocytopenia during Covid-19 Pandemic: An Italian Monocentric Experience [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 1). https://abstracts.isth.org/abstract/immune-thrombocytopenia-during-covid-19-pandemic-an-italian-monocentric-experience/. Accessed September 16, 2021.
« Back to ISTH 2021 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/immune-thrombocytopenia-during-covid-19-pandemic-an-italian-monocentric-experience/